Participated · Equity · Aug 2026

Frontier Power USA acquires late-stage utility-scale battery storage projects and converts them into construction-ready assets, then finances, builds and operates those assets. The company acquired the 200 MW / 800 MWh Blanquilla project, which will use Eos Z3 long-duration battery systems, and placed a roughly $100 million purchase order with Eos for Phase 1. Financing for projects such as Blanquilla is expected to combine Frontier Power USA equity and debt arranged through KKR Capital Markets, and projects will be covered by a Technology Performance Insurance framework arranged with Ariel Green. Stella Energy Solutions is providing development and engineering services for converted projects and has prior experience developing over 4.4 GWh of utility-scale storage. As of the transaction Frontier Power USA has converted 1,280 MWh of usable capacity, is advancing about 5 GWh of acquired/selected/under-diligence projects, and identifies a pipeline of roughly 16 GWh. The company positions this raise and initial purchase order as supporting a repeatable model for acquiring, financing, building and operating battery storage assets.

Participated · Series A · Apr 2026

Quantum Art was spun out of Prof. Roee Ozeri's group at the Weizmann Institute of Science and is led by CEO and co-founder Dr. Tal David, CTO Dr. Amit Ben Kish and CSO Prof. Roee Ozeri. The company focuses on trapped-ion quantum computing and has developed proprietary techniques for multi-qubit gates, scalable modular architectures, and robust quantum error correction. It is advancing a multi-core roadmap including Perspective, a planned 1,000-qubit system aimed at commercial-scale deployment. Quantum Art is transitioning toward commercialization with plans for a Quantum-as-a-Service (QaaS) platform that lets customers move from algorithm development and co-design to execution on its hardware. The company said it is expanding internationally and building partnerships to support early customer adoption while hiring to support development and business growth.

Led · Convertible Note · Dec 2025

Locus Fermentation Solutions (Locus FS) develops and biomanufactures non-GMO, palm-free glycolipid biosurfactants and microbial blends that deliver higher performance and lower toxicity than conventional petrochemical surfactants. Its proprietary fermentation platform is currently the only U.S. source of TSCA-approved glycolipids at commercial scale, enabling adoption across oil & gas, mining, agriculture and industrial/CPG markets. In 2025 the company recorded double-digit growth and added more than 50 new customers, underscoring accelerating commercial traction. Newly raised capital will be directed toward expanding domestic fermentation and downstream processing capacity, launching additional products, broadening distribution and deploying digital analytics tools to optimize operations. Field results show its additives boost oil production, improve metal recovery in mining, raise crop yields and allow formulators to reduce surfactant load while meeting ESG targets. Backed by a deep patent portfolio, Locus FS aims to replace traditional chemistries with cleaner, high-performance alternatives at scale. Total funding secured in 2025 now exceeds $40 million, valuing the company at roughly $100 million.

Participated · Series D · Feb 2022

Hong Kong Asia Medical Group is a cardiovascular specialty medical group founded in 1999 that operates hospitals and services across mainland China, Hong Kong and Japan. The group traces its origins to Wuhan Asia Heart Hospital and has treated about 5 million patients over 22 years. It emphasizes clinical care alongside research and education and has built an internationalized management and talent-development system. The group cites strengths in clinical service capabilities, hospital management replication, clinical innovation translation, and joint talent training. Financially, the company recently completed a $400 million Series D financing. Management says proceeds will support service innovation, continued expansion, and the goal of becoming an international first-class integrated cardiac medicine group combining treatment, patient care, research and education.

Participated · Series B · Jan 2022

Kyverna Therapeutics is a clinical-stage cell therapy company focused on engineering a new class of therapies for autoimmune diseases. Its lead programs, KYV-101 and KYV-201, are anti-CD19 CAR T-cell therapies that target CD19 on B cells. The company is advancing clinical studies in the U.S. and Europe and intends to use recent financing to accelerate those trials. Kyverna specifically highlights applications in autoimmune conditions including lupus nephritis. The company has attracted investment from biopharma and life-science investors backing its clinical-stage programs. Kyverna Therapeutics engineers a new class of cell therapies for serious autoimmune and inflammatory diseases using advanced T-cell engineering and synthetic biology. Its platform includes next-generation CAR T therapies in autologous and allogeneic settings and synReg T cells, a synthetic version of regulatory T cells. The company holds exclusive worldwide licenses from the NIH to use a novel anti-CD19 construct across autologous and allogeneic CAR T therapies. Kyverna intends to advance KYV-101, an autologous anti-CD19 CAR T candidate, into clinical development for B cell-driven autoimmune diseases in the first half of 2022. It is also developing KYV-201 in collaboration with Intellia, combining its CD19 CAR construct with Intellia’s ex vivo CRISPR/Cas9-based allogeneic platform. Kyverna has a strategic collaboration and license agreement with Gilead to develop engineered T-cell therapies based on its synReg platform and Kite’s synNotch technology and is led by CEO Dominic Borie in Emeryville, California. Kyverna Therapeutics is a Berkeley, Calif.-based cell therapy company engineering a new class of therapies for serious autoimmune and inflammatory diseases. It raised $25 million in a Series A equity financing from Vida Ventures and Westlake Village BioPartners. The company’s platform combines advanced T cell engineering and synthetic biology technologies, including a synthetic Treg platform and synNotch™ technology from Kite (a Gilead company), to target autoreactive immune cells at the root cause of disease. Kyverna intends to use the proceeds to advance its therapeutic strategy and to conduct research activities and initial clinical studies through proof-of-concept for programs covered by its collaboration. Kyverna entered a strategic collaboration and license agreement with Gilead under which Gilead paid an upfront $17.5 million and Kyverna may earn up to $570 million in development and commercialization milestones; Gilead has an option to assume further clinical development and commercialization upon exercise. Leadership and board changes accompanied the financing: Fred Cohen of Vida Ventures will serve as chairman; Dominic Borie, M.D., Ph.D., was appointed CEO and will serve on the board; Jeffrey Greve, Ph.D., remains CSO; and investor representatives from Westlake Village BioPartners and Vida Ventures were named to the board. Kyverna will also continue to advance proprietary programs beyond the Gilead collaboration.